利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Synthetic antisense oligodeoxynucleotides targeted to human ache
    1.
    发明授权
    Synthetic antisense oligodeoxynucleotides targeted to human ache 失效
    靶向人类疼痛的合成反义寡脱氧核苷酸

    公开(公告)号：US6121046A

    公开(公告)日：2000-09-19

    申请号：US990065

    申请日：1997-12-12

    申请人： Hermona Soreq ,  Shlomo Seidman ,  Fritz Eckstein ,  Alon Friedman ,  Daniela Kaufer

    发明人： Hermona Soreq ,  Shlomo Seidman ,  Fritz Eckstein ,  Alon Friedman ,  Daniela Kaufer

    IPC分类号： C12N15/09 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  A61P25/00 ,  A61P43/00 ,  C12N20060101 ,  C12N15/113 ,  C12Q1/68 ,  C07H21/04 ,  C12N15/00

    CPC分类号： C12Y301/01007 ,  C12N15/1137 ,  A01K2217/05 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/53

    摘要： A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.

    摘要翻译： 能够选择性调节人乙酰胆碱酯酶（AChE）产生的合成核酸酶抗性反义寡脱氧核苷酸（AS-ODN）和包含至少一种AS-ODN作为活性成分的组合物。 公开了针对针对AChE mRNA剪接信号中的剪接连接的核酸酶抗性反义。 合成的核酸酶抗性AS-ODN能够选择性调节中枢神经系统中的人AChE产生或者能够选择性地降低神经肌肉接头的人类AChE沉积。 本发明还提供了一种在需要这种治疗的患者中恢复脑和脊髓中的平衡胆碱能信号传导或减少神经肌肉接头中的AChE的方法，其通过向需要这种治疗的患者施用治疗有效量的至少一种 的能够选择性调节人AChE生产的合成核酸酶抗性AS-ODN。

    Novel uses of antibodies against AChE and peptides thereof
    2.
    发明申请
    Novel uses of antibodies against AChE and peptides thereof 审中-公开
    抗AChE抗体及其肽的新用途

    公开(公告)号：US20060121536A1

    公开(公告)日：2006-06-08

    申请号：US11352073

    申请日：2006-02-10

    申请人： Hermona Soreq ,  Daniela Kaufer ,  Alon Friedman ,  Shlomo Seidman

    发明人： Hermona Soreq ,  Daniela Kaufer ,  Alon Friedman ,  Shlomo Seidman

    IPC分类号： G01N33/53 ,  C07K16/40

    CPC分类号： C07K16/40 ,  G01N33/6896 ,  G01N2333/918

    摘要： The invention relates to antibodies recognizing acetylcholinesterase or a C-terminal peptide derived from acetyl-cholinesterase, useful in diagnosing central nervous system (CNS) stress, elevated glucocorticoid level, disruption of the blood-brain barrier or Alzheimer's disease. The invention also relates to methods for the diagnosis of central nervous system (CNS) stress, elevated glucocorticoid level or disruption of the blood-brain barrier in a mammal, by use of the antibodies of the invention.

    摘要翻译： 本发明涉及可用于诊断中枢神经系统（CNS）应激，升高的糖皮质激素水平，血脑屏障或阿尔茨海默氏病破坏的乙酰胆碱酯酶或源自乙酰胆碱酯酶的C-末端肽的抗体。 本发明还涉及通过使用本发明的抗体诊断中枢神经系统（CNS）应激，升高的糖皮质激素水平或哺乳动物血脑屏障破坏的方法。

    Uses of antibodies against AChE and peptides thereof
    3.
    发明授权
    Uses of antibodies against AChE and peptides thereof 有权
    使用抗AChE抗体及其肽

    公开(公告)号：US07063948B1

    公开(公告)日：2006-06-20

    申请号：US09980263

    申请日：2000-05-31

    申请人： Hermona Soreq ,  Daniela Kaufer ,  Alon Friedman ,  Shlomo Seidman

    发明人： Hermona Soreq ,  Daniela Kaufer ,  Alon Friedman ,  Shlomo Seidman

    IPC分类号： G01N17/26 ,  C07K16/00 ,  C07K5/00

    CPC分类号： C07K16/40 ,  G01N2800/2821

    摘要： The invention relates to antibodies recognizing acetylcholinesterase or a C-terminal peptide derived from acetyl-cholinesterase, useful in diagnosing central nervous system (CNS) stress, elevated glucocorticoid level, disruption of the blood-brain barrier or Alzheimer's disease. The invention also relates to methods for the diagnosis of central nervous system (CNS) stress, elevated glucocorticoid level or disruption of the blood-brain barrier in a mammal, by use of the antibodies of the invention.

    摘要翻译： 本发明涉及可用于诊断中枢神经系统（CNS）应激，升高的糖皮质激素水平，血脑屏障或阿尔茨海默氏病破坏的乙酰胆碱酯酶或源自乙酰胆碱酯酶的C-末端肽的抗体。 本发明还涉及通过使用本发明的抗体诊断中枢神经系统（CNS）应激，升高的糖皮质激素水平或哺乳动物血脑屏障破坏的方法。

    Method and composition for enabling passage through the blood-brain-barrier
    4.
    发明授权
    Method and composition for enabling passage through the blood-brain-barrier 失效
    能够通过血脑屏障的方法和组成

    公开(公告)号：US06258780B1

    公开(公告)日：2001-07-10

    申请号：US08975084

    申请日：1997-11-20

    申请人： Hermona Soreq ,  Alon Friedman ,  Shlomo Siedman ,  Daniela Kaufer

    发明人： Hermona Soreq ,  Alon Friedman ,  Shlomo Siedman ,  Daniela Kaufer

    IPC分类号： A61K3816

    CPC分类号： C12Y301/01007 ,  A61K31/137 ,  A61K31/138 ,  A61K31/46 ,  A61K38/465 ,  A61K2300/00

    摘要： A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition. The present invention provides a method for administering a compound to the CNS of an animal by subjecting the animal to a stress-mimicking agent or treatment. This agent or treatment facilitates disruption of the blood-brain barrier. During the period that the BBB is opened or disrupted a compound can be administer such that the compound is enabled to passage through the disrupted BBB into the CNS.

    摘要翻译： 一种用于促进化合物通过包含透明试剂ACHE-I4（SEQ ID No：1）剪接变体或I4肽（SEQ ID No：2）及其各自的类似物的药物组合物和药学上可接受的药物组合物 载体被披露。 或者，用于促进化合物通过血脑屏障的药物组合物可以包含肾上腺素，阿托品，多巴胺和/或肾上腺素能组合剂和药学上可接受的载体。 所述组合物可包含至少两种所述试剂。 本发明的组合物可以任选地包括待跨越血脑屏障转运的化合物。 或者，化合物可以与组合物共同施用（同时），或者可以在组合物的作用的生物学有效期间的某一点施用。 本发明提供了通过使动物经受应激模拟剂或治疗而将化合物给予动物的CNS的方法。 该药剂或治疗有助于破坏血脑屏障。 在BBB开放或中断期间，可以给予化合物使得化合物能够通过破坏的BBB进入CNS。

    Parkinson's disease susceptibility haptotype as a tool for genetic screening
    5.
    发明申请
    Parkinson's disease susceptibility haptotype as a tool for genetic screening 审中-公开
    帕金森病易感性结合型作为遗传筛选的工具

    公开(公告)号：US20060166204A1

    公开(公告)日：2006-07-27

    申请号：US10529511

    申请日：2003-09-24

    申请人： Hermona Soreq ,  Liat Ben-Moyal ,  Boris Bryk ,  Alon Friedman

    发明人： Hermona Soreq ,  Liat Ben-Moyal ,  Boris Bryk ,  Alon Friedman

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： Specific PON1 and ACHE alleles segregate in linkage, forming an haplotype which directly correlates with higher susceptibility to develop Parkinson's Disease (PD). This PD-susceptibility haplotype is herein presented as a tool for predicting the risk of developing Parkinson's Disease and its severity, both for an individual and for the population in general. Thus, the present invention provides the use of said PD-susceptibility haplotype in diagnostic and screening methods.

    摘要翻译： 特异性PON1和ACHE等位基因连锁分离，形成与更高易感性发展帕金森病（PD）直接相关的单倍型。 这种PD-易感性单倍型在本文中被提供作为用于预测发展中的帕金森病的风险及其严重程度的工具，无论对于个人和一般人群来说。 因此，本发明提供了所述PD-敏感性单元型在诊断和筛选方法中的用途。